These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31709843)

  • 21. [Allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms].
    Takenaka K
    Rinsho Ketsueki; 2019; 60(9):1148-1156. PubMed ID: 31597838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
    Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary myelofibrosis: update on definition, pathogenesis, and treatment.
    Abdel-Wahab OI; Levine RL
    Annu Rev Med; 2009; 60():233-45. PubMed ID: 18947294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
    Salit RB; Deeg HJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.
    Finazzi MC; Lussana F; Salmoiraghi S; Spinelli O; Rambaldi A
    Expert Rev Hematol; 2017 Jul; 10(7):627-636. PubMed ID: 28504024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
    Passamonti F; Mora B; Barraco D; Maffioli M
    Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel treatments to tackle myelofibrosis.
    Zimran E; Keyzner A; Iancu-Rubin C; Hoffman R; Kremyanskaya M
    Expert Rev Hematol; 2018 Nov; 11(11):889-902. PubMed ID: 30324817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
    Hart C; Klatt S; Barop J; Müller G; Schelker R; Holler E; Huber E; Herr W; Grassinger J
    Haematologica; 2016 Nov; 101(11):1407-1416. PubMed ID: 27662011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review.
    Farhadfar N; Cerquozzi S; Patnaik M; Tefferi A
    J Oncol Pract; 2016 Jul; 12(7):611-21. PubMed ID: 27407157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
    Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L; Medina J; Litvin R; Famulare CA; Patel MA; Maloy M; Castro-Malaspina H; Giralt SA; Weinberg RS; Mascarenhas JO; Mesa R; Rondelli D; Dueck AC; Levine RL; Gupta V; Hoffman R; Rampal RK
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1142-1151. PubMed ID: 30625392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation: The Case of Myelofibrosis.
    Christopeit M; Badbaran A; Alawi M; Flach J; Fehse B; Kröger N
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):e167-e170. PubMed ID: 32147533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing patients with myelofibrosis and low platelet counts.
    Al-Ali HK; Vannucchi AM
    Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.
    Keyzner A; Han S; Shapiro S; Moshier E; Schorr E; Petersen B; Najfeld V; Kremyanskaya M; Isola L; Hoffman R; Mascarenhas J
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2180-2186. PubMed ID: 27596130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
    Garmezy B; Schaefer JK; Mercer J; Talpaz M
    Blood Rev; 2021 Jan; 45():100691. PubMed ID: 32354563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
    Curto-Garcia N; Ianotto JC; Harrison CN
    Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogenic hematopoietic stem cell as curative treatment in myelofibrosis.
    Wardhana ; Datau EA; Rotty LW; Haroen H
    Acta Med Indones; 2011 Oct; 43(4):252-9. PubMed ID: 22156358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.